05/08/2024 | Press release | Distributed by Public on 05/08/2024 15:28
Delaware
|
26-1756290
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
|
9540 Towne Centre Drive, Suite 100
San Diego, California
|
92121
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Thomas A. Coll, Esq.
Su Lian Lu, Esq.
Cooley LLP
10265 Science Center Drive
San Diego, California 92121
(858) 550-6000
|
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
(858) 888-7600
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
Emerging growth company
|
☐
|
Item 3.
|
Incorporation of Documents by Reference.
|
(a) |
The contents of the earlier registration statements on Form S-8 filed with the SEC on August 28, 2018 (File No. 333-227073), March 29, 2019 (File No. 333-230589), March 11, 2020 (File No. 333-237069), August 14, 2020 (File No. 333-245764), March 24, 2021 (File No. 333-254654), March 1, 2022 (File No. 333-263176), and March 9, 2023 (File No. 333-270430);
|
|
(b) |
The Registrant's Annual Report on Form 10-K for the year ended December 31, 2023, which included audited financial statements for the Registrant's latest fiscal year, filed with the SEC on March 5, 2024;
|
(c) | The Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 8, 2024; |
(d) | The Registrant's Current Reports on Form 8-K filed with the SEC on February 28, 2024, March 5, 2024, April 5, 2024, April 8, 2024, and May 8, 2024; and |
|
(e) |
The description of the Registrant's Common Stock contained in a registration statement on Form 8-A filed with the SEC on July 31, 2018 (File No. 001-38613) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including any amendment or report filed for the purpose of updating such description including Exhibit 4.5 of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 5, 2024.
|
Item 8.
|
Exhibits.
|
Exhibit
Number
|
Description
|
|
4.1(1)
|
||
4.2(2)
|
||
4.3(3)
|
||
4.4(4)
|
||
5.1
|
Opinion of Cooley LLP.
|
|
23.1
|
Consent of BDO USA, P.C., Independent Registered Public Accounting Firm.
|
|
23.2
|
Consent of Cooley LLP. Reference is made to Exhibit 5.1.
|
|
24.1
|
Power of Attorney. Reference is made to the signature page hereto.
|
|
99.1(5)
|
||
99.1A(6)
|
||
99.1B(7)
|
||
99.1C(8)
|
||
99.1D(9)
|
||
99.1E(10)
|
||
99.2(11)
|
||
107
|
Filing Fee Table.
|
(1)
|
Incorporated by reference to Exhibit 3.1 of the Registrant's Quarterly Report on Form 10-Q, filed with the SEC on November 8, 2023.
|
(2)
|
Incorporated by reference to Exhibit 3.2 of the Registrant's Current Report on Form 8-K, filed with the SEC on August 24, 2018.
|
(3)
|
Incorporated by reference to Exhibit 3.2 of the Registrant's Current Report on Form 8-K, filed with the SEC on April 14, 2023.
|
(4)
|
Incorporated by reference to Exhibit 4.1 of the Registrant's Annual Report on Form 10-K, filed with the SEC on March 5, 2024.
|
(5)
|
Incorporated by reference to Exhibit 99.1 of the Registrant's Registration Statement on Form S-8 (File No. 333-245764), filed with the SEC on August 13, 2020.
|
(6)
|
Incorporated by reference to Exhibit 10.2A of the Registrant's Annual Report on Form 10-K, filed with the SEC on March 9, 2023.
|
(7)
|
Incorporated by reference to Exhibit 10.2B of the Registrant's Annual Report on Form 10-K, filed with the SEC on March 9, 2023.
|
(8)
|
Incorporated by reference to Exhibit 10.2C of the Registrant's Annual Report on Form 10-K, filed with the SEC on March 9, 2023.
|
(9)
|
Incorporated by reference to Exhibit 10.5 of the Registrant's Registration Statement on Form S-1 (File No. 333-225970), as amended, filed with the SEC on August 17, 2018.
|
(10)
|
Incorporated by reference to Exhibit 10.1 of the Registrant's Quarterly Report on Form 10-Q, filed with the SEC on August 4, 2021.
|
(11)
|
Incorporated by reference to Exhibit 99.5 of the Registrant's Registration Statement on Form S-8 (File No. 333-227073), filed with the SEC on August 28, 2018.
|
BIONANO GENOMICS, INC.
|
||
By:
|
/s/ R. Erik Holmlin, Ph.D.
|
|
R. Erik Holmlin, Ph.D.
|
||
President and Chief Executive Officer
|
Signature
|
Title
|
Date
|
||
/s/ R. Erik Holmlin, Ph.D.
|
President, Chief Executive Officer and Director
(Principal Executive Officer)
|
May 8, 2024
|
||
R. Erik Holmlin, Ph.D.
|
||||
/s/ Gülsen Kama
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
May 8, 2024
|
||
Gülsen Kama
|
||||
/s/ David L. Barker, Ph.D.
|
Director
|
May 8, 2024
|
||
David L. Barker, Ph.D.
|
||||
/s/ Yvonne Linney, Ph.D.
|
Director
|
May 8, 2024
|
||
Yvonne Linney, Ph.D.
|
||||
/s/ Albert A. Luderer, Ph.D.
|
Director
|
May 8, 2024
|
||
Albert A. Luderer, Ph.D.
|
||||
/s/ Hannah Mamuszka
|
Director
|
May 8, 2024
|
||
Hannah Mamuszka
|
||||
/s/ Aleksandar Rajkovic, M.D., Ph.D.
|
Director
|
May 8, 2024
|
||
Aleksandar Rajkovic, M.D., Ph.D.
|
||||
/s/ Christopher Twomey
|
Director
|
May 8, 2024
|
||
Christopher Twomey
|
||||
/s/ Kristiina Vuori, M.D., Ph.D.
|
Director
|
May 8, 2024
|
||
Kristiina Vuori, M.D., Ph.D.
|
||||
/s/ Vincent Wong, J.D., M.B.A.
|
Director
|
May 8, 2024
|
||
Vincent Wong, J.D., M.B.A.
|